Results 131 to 140 of about 6,010 (179)

Case report: Successful use of sotatercept to treat pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia. [PDF]

Respir Med Case Rep
Ramakrishnan A, Olitsky S, Saggar R, Channick RN, McWilliams JP.   +4 more
europepmc   +1 more source

Methamphetamine-Associated Pulmonary Arterial Hypertension in a Japanese Pulmonary Hypertension Referral Center. [PDF]

Circ Rep
Fujisaki S, Kuraishi A, Takano R, Hayashi H, Asano R, Ogo T.   +5 more
europepmc   +1 more source

Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment. [PDF]

Pulm Circ
Satoh T, Tamura Y, Takama N, Matsubara H, Tanabe N, Inami T, Hiraide T, Abe K, Dohi Y, Ogihara Y, Ogo T, Adachi S, Nakazato K, Tsujino I, Ota H, Komaru K, Sato H, Tezuka Y, Ono Y, Suda R, Hosokawa K, Isobe S, Kiko T, Koga Y, Nakamura J, Sugimura K, Hatano M, Fukumoto Y, Yasuda S.   +28 more
europepmc   +1 more source

A Case Series: Pericardial Effusion in Patients Treated With Sotatercept. [PDF]

Pulm Circ
McKenna AM, Hill NS, Farber HW.
europepmc   +1 more source

Nebulized Treprostinil in Mechanically Ventilated Children. [PDF]

Pediatr Pulmonol
Cohen SP, Paulus D, Hattie A, Malehorn B, Irmen M, Gajarski R.   +5 more
europepmc   +1 more source

Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension [PDF]

Respiratory Medicine, 2013
SummaryBackgroundTransition from intravenous (IV) epoprostenol to IV treprostinil in patients with pulmonary hypertension (PH) has traditionally been performed by gradually decreasing the epoprostenol dose while increasing the treprostinil dose ...
R A Dweik
exaly   +2 more sources